title: [Efficacy of a Dexamethasone Implant for the Treatment of Refractory Cystoid Macular Oedema in Non-Infectious Uveitis].
abstract: OBJECTIVE
  To evaluate the efficacy of an intravitreal dexamethasone implant (Ozurdex®) in patients with cystoid macular oedema (CME) suffering from non-infectious uveitis.
  
  
  METHODS
  Monocentric, retrospective, single-arm analysis in 49 patients (59 implanted eyes) with inactive uveitis, in whom CME had been unresponsive to corticosteroids and/or immunosuppressants and systemic acetazolamide, and who received a dexamethasone implant. Patients were followed up at 6, 12 and 24 weeks after unilateral (n = 39)/bilateral (n = 10) implantation. The primary outcome measure was central foveal thickness (CFT), as measured by Spectralis optical coherence tomography (OCT); secondary outcome measures were improvement in best-corrected visual acuity (BCVA), laser flare photometry and safety measures, including intraocular pressure (IOP) and cataract progression.
  
  
  RESULTS
  At 6, 12 and 24 weeks, mean CFT was reduced (≥ 20 %) in 68, 44 and 45 % and BCVA improved (≥ 2 lines) in 47, 40 and 26 %, respectively, as compared to baseline. At 6, 12 and 24 weeks, significant flare reduction was observed in 70, 41, and 42 %, respectively. Cumulative cataract progression was observed in 12, 18 and 31 % at 6, 12 and 24 weeks, respectively. IOP ≥ 22 mmHg was noted in 5 % at baseline and in 21, 3, and 0 % at 6, 12 and 24 weeks, respectively.
  
  
  CONCLUSIONS
  In uveitis patients with CME refractory to systemic anti-inflammatory drugs, the dexamethasone implant improves CME transiently. However, IOP increase and cataract progression are common side effects.
authors.affiliation: Augenabteilung am St. Franziskus-Hospital, Münster.
authors.forename: M
authors.initials: M
authors.lastname: Breitbach
authors.affiliation: Augenabteilung am St. Franziskus-Hospital, Münster.
authors.forename: D
authors.initials: D
authors.lastname: Rack
authors.affiliation: Augenabteilung am St. Franziskus-Hospital, Münster.
authors.forename: M
authors.initials: M
authors.lastname: Dietzel
authors.affiliation: Universitätsaugenklinik Essen, Universität Diusburg-Essen.
authors.forename: C
authors.initials: C
authors.lastname: Heinz
authors.affiliation: Universitätsaugenklinik Essen, Universität Diusburg-Essen.
authors.forename: A
authors.initials: A
authors.lastname: Heiligenhaus
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D002908:Chronic Disease; D003907:Dexamethasone / Q000008:administration & dosage*; D004343:Drug Implants / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome; D014605:Uveitis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D014786:Vision Disorders / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D014792:Visual Acuity / Q000187:drug effects; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D004343:Drug Implants; D003907:Dexamethasone